Processing...
Clinical Trials for Ovarian Cancer
Search
Search
There are 212 active trials for advanced/metastatic ovarian cancer.
Click on a trial to see more information.
212 trials meet filter criteria.
Sort by:
HealthScout AI summary: This trial enrolls adults with advanced, FAP-positive solid tumors who have progressed on or lack standard therapy, using [203Pb]Pb-PSV359 SPECT imaging to confirm FAP expression and [212Pb]Pb-PSV359, a FAP-targeted alpha-emitting peptide-radiopharmaceutical, for systemic therapy.
ClinicalTrials.gov ID: NCT06710756
HealthScout AI summary: Adults with advanced solid tumors receive first-in-human BMS-986500 monotherapy (with a dedicated expansion for CCNE1-amplified ovarian cancer); separate cohorts enroll advanced breast cancer previously treated with a CDK4/6 inhibitor to receive BMS-986500 combined with palbociclib plus fulvestrant. BMS-986500’s molecular target/mechanism is undisclosed; the study focuses on safety/PK and dose finding with exploratory efficacy by RECIST.
ClinicalTrials.gov ID: NCT06997029
HealthScout AI summary: Adults with advanced/metastatic breast, ovarian, or prostate cancer (including patients with known brain metastases), ECOG 0–1, and measurable disease receive oral DSB2455, a PARP1‑selective inhibitor aiming to exploit synthetic lethality in HR‑deficient tumors (e.g., BRCA/HRR alterations); prior first‑line PARP inhibitor exposure is allowed, but prior PARP1‑selective therapy is excluded. Single‑arm dose escalation/expansion evaluates safety and preliminary activity, with CNS penetration highlighted and mandatory biopsies required.
ClinicalTrials.gov ID: NCT06458712
HealthScout AI summary: Adults with metastatic or unresectable solid tumors harboring AKT/PI3K/PTEN pathway alterations (excluding concurrent EGFR/KRAS/NRAS/HRAS/BRAF drivers) receive the investigational AKT-pathway inhibitor TER-2013 as monotherapy (expansion in ovarian/cervical/SCCHN/lung/esophageal and endometrial cancers) or with fulvestrant for HR+/HER2- breast cancer previously treated with an aromatase inhibitor. Prior AKT/PI3K/PTEN inhibitors (and prior SERD/mTOR in combo expansion) are excluded; requires ECOG 0–1 and adequate organ function.
ClinicalTrials.gov ID: NCT07109726
HealthScout AI summary: Adults with advanced solid tumors harboring AKT1 E17K mutations, including a cohort with HR+/HER2- metastatic breast cancer, receive the oral selective AKT1 E17K allosteric inhibitor ATV-1601 as monotherapy or in combination with fulvestrant. The trial excludes tumors with activating RAS/BRAF mutations and aims to identify dosing and preliminary activity while minimizing AKT2-related metabolic toxicities.
ClinicalTrials.gov ID: NCT07038369
HealthScout AI summary: Adults with mesothelin-expressing advanced solid tumors (ECOG 0–1) receive weekly IV CT-95 (LNK-101), a mesothelin × CD3 T‑cell–engaging bispecific antibody engineered for reduced off‑tumor activation, in a dose-escalation/expansion study. Excludes prior mesothelin-targeted CD3/CAR‑T therapy; evaluates safety, PK, and preliminary efficacy across tumor types including mesothelioma.
ClinicalTrials.gov ID: NCT06756035
HealthScout AI summary: Adults with mesothelin-expressing recurrent/relapsed advanced ovarian (including primary peritoneal/fallopian tube), cholangiocarcinoma, or epithelial mesothelioma (pleural/peritoneal), ECOG 0–1, after ≥1 prior therapy, receive lymphodepleting chemotherapy followed by a single infusion of SynKIR-110, an autologous T-cell therapy using a mesothelin-targeted KIR-CAR (activating KIR plus DAP12) designed to enhance persistence/function in solid tumors. Excludes prior gene-engineered T-cell therapy, sarcomatoid/biphasic mesothelioma, active viral infections, significant pulmonary disease, and active autoimmune disease.
ClinicalTrials.gov ID: NCT05568680
HealthScout AI summary: Adults with advanced/metastatic solid tumors or relapsed/refractory non-Hodgkin’s lymphoma (ECOG 0–2) who have exhausted standard options receive once-daily oral APG-5918, an EED inhibitor that allosterically disrupts PRC2 to deplete H3K27me3. Expansion focuses on molecular subsets including EZH2-mutant B‑cell lymphomas, SMARCB1-deficient sarcomas (epithelioid preferred), and castration‑resistant prostate cancer; treated/stable brain mets allowed.
ClinicalTrials.gov ID: NCT05415098
HealthScout AI summary: Adults with TROP2-positive, platinum-resistant ovarian/peritoneal/fallopian tube cancer, mesonephric-like adenocarcinoma, or pancreatic/ampullary cancer with peritoneal/retroperitoneal disease receive lymphodepleting cyclophosphamide/fludarabine followed by a single intraperitoneal infusion of allogeneic cord blood–derived NK cells engineered with a TROP2-directed CAR and IL-15 for persistence. Designed to assess safety and preliminary efficacy of intraperitoneal TROP2 CAR-NK in heavily pretreated patients without active CNS disease or contraindications to IP therapy.
ClinicalTrials.gov ID: NCT05922930
HealthScout AI summary: Adults with advanced, HLA‑G–positive solid tumors (ECOG 0–1) after standard therapies receive leukapheresis, fludarabine/cyclophosphamide lymphodepletion, then a single infusion of IVS‑3001, an autologous third‑generation CAR‑T targeting HLA‑G (an immune checkpoint ligand for ILT2/ILT4). Phase 2a includes cohorts for clear cell RCC post‑CPI/TKI, epithelial ovarian cancer post‑platinum (± prior PARP if BRCA1/2‑mutant), and other HLA‑G+ tumors without standard options.
ClinicalTrials.gov ID: NCT05672459